Peer-reviewed veterinary case report
Radiation and carboplatin treatment for oral cancer in cats
By Fidel, J et al.·Published in Journal of veterinary internal medicine·2011·Washington State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of oral squamous cell carcinoma with accelerated radiation therapy and concomitant carboplatin in cats.
- Species:
- cat
Plain-English summary
A group of cats with oral squamous cell carcinoma (SCC), a serious type of mouth cancer, underwent a new treatment combining accelerated radiation therapy with a chemotherapy drug called carboplatin. The cats received radiation over nine days, along with carboplatin on specific days during treatment. The results showed that the average survival time for these cats was about 319 days, with some cats living much longer, especially those with tumors in the tonsils or cheek. This treatment approach appears to provide better survival rates compared to older methods, offering hope for cats diagnosed with this challenging condition.
People also search for: cat oral cancer treatment · feline squamous cell carcinoma survival · carboplatin for cats with cancer
Abstract
BACKGROUND: Feline oral squamous cell carcinoma (SCC) carries a very poor prognosis with traditional treatments. HYPOTHESIS/OBJECTIVES: To examine the effectiveness of adding carboplatin to a previously published accelerated radiation protocol in the treatments of oral SCC in cats. ANIMALS: Thirty-one cases of oral SCC in cats. Tumor sites included lingual (n = 9), mandible (n = 10), maxilla (n = 7), tonsil (n = 4), and cheek (n = 1). METHODS: Prospective trial using a planned radiation protocol consisting of 14 fractions of 3.5 Gy given within a 9-day period with the addition of carboplatin given at 90-100 mg/m(2) on day 1 and day 4.5. Treatments were twice daily with a 6-hour delay between treatments. All cats presenting with oral SCC without evidence of distant metastasis were eligible. RESULTS: Median survival for all cats was 163 days (range 53-770 days) with a mean of 319 ± 53 days with significant predictors of survival being site (P = .004) and whether there was a complete response at 30 days (P = .001). Cats with tumors of tonsil origin or cheek responded best to therapy and were long-term survivors with a mean survival of 724 days and the median had not been reached because of continued survival of 4 cats. CONCLUSIONS AND CLINICAL IMPORTANCE: This protocol offers an aggressive yet tolerable treatment of oral SCC in cats that might offer improved survival as compared with previously reported treatments. The long-term survival of cats with tonsillar SCC has not been reported previously.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21539605/